South San Francisco, Calif., - April 1, 2004 - FibroGen, Inc., today announced the recent publication of three scientific articles featuring hemostatic, drug delivery, and tissue engineering applications of the Company's proprietary recombinant human collagens and gelatins. Produced using fully synthetic and reproducible processes, FibroGen's recombinant collagens and gelatins provide highly pure and fully characterized replacements for animal-sourced collagen and gelatin in a variety of medical device and pharmaceutical applications. The Company also announced its 2004 presentation and exhibition schedule.

Master File applications are in preparation for FibroGen's recombinant human collagen type III, which has hemostatic properties superior to those of bovine collagen type I, and for 8.5 kDa recombinant gelatin, which has completed human safety testing demonstrating its suitability for use in drug delivery. The Company offers clinical-grade and research materials for evaluation.

Reprint requests should be directed to FibroGen for the following articles:

• Yang C, Hillas P, Tang J, Balan J, Notbohm H, Polarek J. Development of a recombinant human collagen-type III based hemostat. J Biomed Mater Res. 2004 Apr 15;69B(1):18-24.
• Yang C, Hillas PJ, Baez JA, Nokelainen M, Balan J, Tang J, Spiro R, Polarek JW. The application of recombinant human collagen in tissue engineering. BioDrugs. 2004;18(2):103-19.
• Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, Carmichael D, Perala M, Hamalainen ER, Jarvinen M, Polarek J. Recombinant collagen and gelatin for drug delivery. Adv Drug Deliv Rev. 2003 Nov 28;55(12):1547-67.

• 227th American Chemical Society National Meeting, Anaheim, CA, March 28 - April 1
• 7th World Biomaterials Congress, Sydney, Australia, May 17 - 21
• 7th Annual Conference on Vaccine Research, Arlington, VA, May 24 - 26
• 2nd Pharmaceutical Sciences World Congress, Kyoto, Japan, May 29 - June 3
• American Association of Pharmaceutical Scientists, Baltimore, MD, November 7 - 11

FibroGen, Inc., is a privately held biotechnology company focused on the discovery, development, and commercialization of therapeutics, recombinant human collagens, and recombinant gelatins to address unmet needs in the medical, pharmaceutical, and consumer markets. FibroGen's therapeutic target areas include fibrosis, anemia, and ischemia.

For more information about FibroGen, Inc., please visit www.fibrogen.com.

Contact:
Virginia Finnerty-Brooks (business development), 650-866-7825
Laura Hansen (investors/media), 650-866-7223